Expert Insights

Ajay Nooka, MD, discusses topline results from the phase 3 MonumenTAL-6 trial evaluating talquetamab-based combinations in early relapsed multiple myeloma, highlighting significant progression-free survival benefits and the potential for...

Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer following...

John Mascarenhas, MD, presents a case of hydroxyurea resistance and intolerance in essential thrombocythemia, highlighting the clinical decision to transition to ropeginterferon alfa-2b.

Naseema Gangat, MBBS, discusses results from the phase 2 RESTORE-PV trial evaluating DISC-3405 in patients with polycythemia vera, highlighting reductions in therapeutic phlebotomy requirements, improvements in patient-reported symptoms, and...

Naseema Gangat, MBBS, discusses results from the phase 2 RALLY-MF trial evaluating selcodebart for anemia in patients with myelofibrosis, highlighting durable hematologic responses across transfusion requirements, activity regardless of...

Diana Osorio, MD, MPH, discusses the clinical significance of BRAF V600E in pediatric cervicomedullary ganglioglioma, highlighting the role of molecular profiling in guiding BRAF/MEK-targeted therapy and the practical considerations of...

Geoffrey Ku, MD, discusses findings from the phase 3 HERIZON-GEA-01 trial evaluating first-line zanidatamab plus chemotherapy, with or without tislelizumab, in patients with HER2-positive gastroesophageal adenocarcinoma, highlighting improved...